🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Minimally Invasive Coronary Artery Bypass Supported by Cangrelor

Recruitingn/aAges 18 Years - anyAllCardiocentro Ticino
NCT07514962 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip. The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand. Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications? Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure. This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outco

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria for the historical control arm: * Age ≥18 years old * CABG with IMA-LAD graft in MIDCAB technique Inclusion criteria for the prospective arm: * Age ≥18 years old * CABG with IMA-LAD graft in MIDCAB technique * Signed informed consent Exclusion criteria for the historical control arm * Administration of fibrinolytics or GP IIb/IIIa inhibitors * Previous intracranial hemorrhage * Known bleeding diathesis * Patients undergoing concomitant PCI and MIDCAB * Severe renal or liver disease * Pregnancy or breast feeding Exclusion criteria for the prospective arm * Unconsciousness * Known hypersensitivity to study drug (cangrelor) * Recent administration of fibrinolytics or GP IIb/IIIa inhibitors * Previous intracranial hemorrhage * Known bleeding diathesis * Patients undergoing concomitant PCI and MIDCAB * Severe renal or liver disease * Pregnancy or breast feeding
💊

What it tests

  • Cangrelor-guided MIDCAB surgery (for the prospective cases)
  • Aspirin MIDCAB surgery (for the historical controls)
📍

Where

1 site
Istituto Cardiocentro Ticino
Lugano, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy